Ovid Therapeutics Inc. (OVID) — DEF 14A Filings
All DEF 14A filings from Ovid Therapeutics Inc.. Browse 3 Proxy Statement reports with AI-powered summaries and risk analysis.
DEF 14A Filings (3)
-
Ovid Seeks 152% Stock Authorization Hike for PIPE Financing
— Nov 7, 2025 Risk: high
Ovid Therapeutics Inc. is seeking stockholder approval for three critical proposals at a Special Meeting on December 11, 2025, to facilitate a significant PIPE -
Ovid Therapeutics Details 2024 Executive Equity Compensation
— May 22, 2025 Risk: low
Ovid Therapeutics Inc.'s DEF 14A filing, dated May 22, 2025, primarily details executive compensation and equity award information for the fiscal year ended Dec -
Ovid Therapeutics Inc. Files Definitive Proxy Statement
— Apr 24, 2024 Risk: low
Ovid Therapeutics Inc. (OVID) filed a Proxy Statement (DEF 14A) with the SEC on April 24, 2024. Ovid Therapeutics Inc. filed a Definitive Proxy Statement (DEF 1
Popular Companies
AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX